BTK and B-cell chronic lymphocytic leukemia: Patients with CLL present a higher risk of bleeding [3], and those undergoing ibrutinib treatment present inhibition of BTK-dependent platelet aggregation [3], with a more common occurrence of low-grade bleeding (35% vs. 15%) [3] and major hemorrhage (4.4 vs. 2.8%) [3] versus comparative therapy.